Global Cord Blood Corporation

CO | $2.9876 -2.1%

(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-51.42% volume)
Earnings Calendar:
Market Cap: $ 363,145,992
http://www.globalcordbloodcorp.com
Sec Filling | Patents | 1260 employees

Global Cord Blood operates as a holding company, which engages in the provision of cord blood banking services. It provides cord blood processing and storage service. The company also offers cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services. It preserves cord blood units donated by the public and provides matching services on such donated units and deliver matching units to patients in need of transplants. Global Cord Blood was founded on January 17, 2008 and is headquartered in Hong Kong.

stem cell t-cell msa ceiling

add to watch list Paper trade email alert is off

Biocept, Inc.

BIOC | $0.4349 -10.32% 750K

Health Services

(0.0% 1d) (0.0% 1m) (25.7% 1y) (0.0% 2d) (0.0% 3d) (-13.1% 7d) (-9.6% volume)
Earnings Calendar: 2023-04-17
Market Cap: $ 1,142,059
http://www.biocept.com
Sec Filling | Patents | 88 employees

(US) Biocept, Inc. is an oncology laboratory service company, which focuses on the development and marketing of novel laboratory products in the detection of rare cells to include circulating tumor cells. It develops and commercializes proprietary circulating tumor cell and circulating tumor DNA tests utilizing a standard blood sample. The company utilizes cell enrichment and extraction technology for the detection and analysis of circulating tumor DNA tests. It also offers services to other laboratory testing providers, academic institutions, research organizations, biopharmaceutical companies and clinical trial support and specific oncogenic alterations. Biocept was founded on May 12, 1997 and is headquartered in San Diego, CA.

tumor cells t-cell clinical trials ceiling

add to watch list Paper trade email alert is off

Biodesix, Inc.

BDSX | $1.24 -0.8% -0.81% 48K

Health Services

(0.0% 1d) (-7.4% 1m) (-29.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (12.25% volume)
Earnings Calendar: 2022-11-03
Market Cap: $ 120,208,156
http://www.biodesix.com
Sec Filling | Patents | n/a employees

Biodesix, Inc. provides blood-based diagnostics services for patients with lung disease. It offers GeneStrat, a genomic blood test for patients who have been diagnosed with advanced lung cancer; and VeriStrat, a serum proteomic test that provides prognostic and predictive information for patients with non-small cell lung cancer. It is a data-driven diagnostic solutions company with proprietary AI platform to discover, develop, and commercialize solutions for clinical unmet needs, with a primary focus in lung disease. The firm offers six diagnostic tests including: Nodify XL2, Nodify CDT, GeneStrat, VeriStrat, Bio-Rad SARS-CoV-2 ddPCR test and the Platelia SARS-CoV-2 test. . The company was founded in 2005 and is headquartered in Boulder, CO.

cancer lung cancer genomic t-cell lungs diagnostics ceiling

add to watch list Paper trade email alert is off

Protalix BioTherapeutics, Inc.

PLX | $1.15 1.77% -2.61% 450K

Health Services

(0.0% 1d) (-15.7% 1m) (-51.5% 1y) (0.0% 2d) (-1.7% 3d) (-0.9% 7d) (16.61% volume)
Earnings Calendar:
Market Cap: $ 84,009,943
http://www.protalix.com
Sec Filling | Patents | 196 employees

(IL) Protalix Biotherapeutics, Inc. engages in the development, production, and commercialization of recombinant therapeutic proteins based on plant cell based expression system. Its products include Alidornase alfa and OPRX-106. The company was by Yoseph Shaaltiel in 1993 and is headquartered in Karmiel, Israel.

israel t-cell ceiling

add to watch list Paper trade email alert is off